Alternative schedules or integration strategies to maximise treatment duration with sunitinib in patients with gastrointestinal stromal tumours

Gastrointestinal stromal tumours (GISTs) are the most common mesenchymal tumour of the gastrointestinal tract. The advent of targeted kinase-inhibitors has revolutionised treatment strategies and clinical outcomes for patients with advanced GIST. In the majority of countries, sunitinib is the only a...

Descripción completa

Detalles Bibliográficos
Autores principales: SAPONARA, MARISTELLA, LOLLI, CRISTIAN, NANNINI, MARGHERITA, DI SCIOSCIO, VALERIO, SERRA, CARLA, MANDRIOLI, ANNA, PALLOTTI, MARIA CATERINA, BIASCO, GUIDO, PANTALEO, MARIA ABBONDANZA
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2014
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4156266/
https://www.ncbi.nlm.nih.gov/pubmed/25202412
http://dx.doi.org/10.3892/ol.2014.2348

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4156266/
https://www.ncbi.nlm.nih.gov/pubmed/25202412
http://dx.doi.org/10.3892/ol.2014.2348

Ejemplares similares